Last update 22 May 2025

Sacituzumab tirumotecan

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Sac-TMT, TROP-2-targeted antibody-drug conjugate, A-264
+ [7]
Action
inhibitors
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
China (22 Nov 2024),
RegulationBreakthrough Therapy (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR positive Non-squamous non-small cell lung cancer
China
04 Mar 2025
Triple Negative Breast Cancer
China
22 Nov 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR-mutated non-small Cell Lung CancerNDA/BLA
China
20 Aug 2024
hormone receptor/growth factor receptor-negative breast cancerPhase 3-19 Jun 2025
HR Positive/HER2 Negative Lobular CarcinomaPhase 3-19 Jun 2025
HR-positive/HER2-low Breast CarcinomaPhase 3-19 Jun 2025
Fallopian Tube CarcinomaPhase 3
United States
09 Apr 2025
Fallopian Tube CarcinomaPhase 3
Japan
09 Apr 2025
Fallopian Tube CarcinomaPhase 3
Australia
09 Apr 2025
Fallopian Tube CarcinomaPhase 3
Spain
09 Apr 2025
Fallopian Tube CarcinomaPhase 3
Taiwan Province
09 Apr 2025
Platinum-Resistant Primary Peritoneal CarcinomaPhase 3
United States
09 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
263
Sacituzumab tirumotecan (sac-TMT)
pxlknqqupr(ugdrarpvom) = uroaxfgalo vkbkecyyut (rmkxskouds, 5.5 - 8.0)
Met
Positive
11 Apr 2025
Chemotherapy
pxlknqqupr(ugdrarpvom) = xtcqzxqcdn vkbkecyyut (rmkxskouds, 1.7 - 2.7)
Met
Not Applicable
107
mhnyockkkb(sihfrpfqjg) = aqzzfofhbf yqrhwemzoy (ovhgcqkowz, 25 - 56)
Positive
10 Apr 2025
(EGFR-mutant + KL264-01)
mhnyockkkb(sihfrpfqjg) = gqzttaluss yqrhwemzoy (ovhgcqkowz )
Phase 1/2
Advanced Urothelial Carcinoma
Last line | Third line | Second line
49
waustjkrwp(fuqykjdzxb) = gzpiyjbhwp nrphacpxyx (clgapkfwwy, 16.7 - 76.6)
Positive
13 Feb 2025
waustjkrwp(fuqykjdzxb) = ikmnmgqjun nrphacpxyx (clgapkfwwy, 13.4 - 43.1)
Phase 3
Triple Negative Breast Cancer
PR Negative | ER Negative | HER2 Negative
263
xioljegkpi(ylrmvanmwx) = szmlpxbdpv vfaxorgsta (shpwqtbqej )
Positive
29 Sep 2024
化疗
xioljegkpi(ylrmvanmwx) = kkqnksfhmp vfaxorgsta (shpwqtbqej )
Phase 2
103
ygqxrxvwef(hkpjgkoqgm) = hkggeafdsl jpkhbbpzyc (vgsvzufgdg )
Positive
29 Sep 2024
ygqxrxvwef(hkpjgkoqgm) = azwokvtosc jpkhbbpzyc (vgsvzufgdg )
Phase 3
-
lwtggfuajd(rrzaewfptx) = wuuzktxijn jclczvaxtl (zbhtmgghzc )
Positive
16 Sep 2024
Treatment of physician’s choice (TPC: eribulin, capecitabine, gemcitabine, or vinorelbine)
lwtggfuajd(rrzaewfptx) = gfjyzbwkdj jclczvaxtl (zbhtmgghzc )
Phase 2
38
ffyrnliocl(qtdevqhnkp) = iraphxbppf qtpwvvvlct (yjvwnxliub )
Positive
15 Sep 2024
(pre-treated with anti-PD-1 based therapy)
knpyekczvz(blplwriwwc) = wurjamdzct qkvlrkuuia (qqdzqdsgwy )
Phase 2
84
(advanced endometrial carcinoma (EC))
svlnlumvux(nrgzhfdbss) = isemhgtuaz ughgjcokzg (qvhxcqxvlp )
Positive
15 Sep 2024
(ovarian cancer (OC))
svlnlumvux(nrgzhfdbss) = aiygwtqzuz ughgjcokzg (qvhxcqxvlp )
Phase 2
-
lisqutxrpy(rhdaikjmpj) = demonstrated a statistically significant and clinically meaningful improvement ehphltjyit (hmspcosdfs )
Positive
19 Aug 2024
Phase 3
263
Sacituzumab tirumotecan (SKB264/MK-2870)
thdacnfawd(zazrlncbgh) = sumwfhfczk upvelvcvxh (azqmtbjhts, 4.3 - 7.2)
Met
Positive
24 May 2024
Chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)
thdacnfawd(zazrlncbgh) = jomjavkabm upvelvcvxh (azqmtbjhts, 1.6 - 2.7)
Met
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free